RxDoctor Payments Data

Dan Liu

Ophthalmology · Worcester, MANPI 1033565874

Payments from drug & device makers

$2,061in general payments, 2019–2025

Across 56 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$805
  • AbbVie$307
  • Oyster Point Pharma, Inc.$211
  • Sight Sciences, Inc.$191
  • Dompe US, Inc.$126
  • Glaukos Corporation$107
  • plus $315 from 6 others

What the payments were for

  • Travel & lodging$43521%
  • Food & beverage$1,62779%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,061 in reported general payments places this provider in the 60th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$309,331
Medicare patients
832
Services billed
2,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$66,902
XiidraLifitegrast26$35,856
Prednisolone Acetate401$20,640
Cyclosporine18$13,719
Restasis MultidoseCyclosporine12$12,526
TyrvayaVarenicline Tartrate14$11,764
Ketorolac Tromethamine252$6,267
Ofloxacin270$4,572
Famciclovir18$3,278
ValacyclovirValacyclovir Hcl49$2,639
Brimonidine Tartrate25$1,645
Latanoprost85$1,573
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha62$682
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$520
Timolol Maleate39$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose$307$79,42758 claims
Bausch & Lomb Americas Inc.Xiidra$48$35,85626 claims
Oyster Point Pharma, Inc.Tyrvaya$211$11,76414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →